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 2 
Abstract 
Recurrent urinary tract infections (UTIs) pose a significant burden on the health care system.  
Underlying mechanisms predisposing children to UTIs and associated changes in the urinary 
proteome are not well understood. We aimed to investigate the urinary proteome of a subset of 
children who have vesicoureteral reflux (VUR) and recurrent UTIs because of their risk of 
developing infection-related renal damage. Improving diagnostic modalities to identify UTI risk 
factors would significantly alter the clinical management of children with VUR. We profiled the 
urinary proteomes of 22 VUR patients with low grade VUR (1-3 out of 5), a history of recurrent 
UTIs, and renal scarring, comparing them to those obtained from 22 age-matched controls. Urinary 
proteins were analyzed by mass spectrometry followed by protein quantitation based on spectral 
counting. Of the 2,551 proteins identified across both cohorts, 964 were robustly quantified, as 
defined by meeting criteria with spectral count (SC) ≥2 in at least 7 patients in either VUR or 
control cohort based on optimization of signal-to-noise ratio. Eighty proteins had differential 
expression between the two cohorts, with 44 proteins significantly upregulated and 36 
downregulated (q<0.075, |FC| >1.2). Urinary proteins involved in inflammation, acute phase 
response (APR), modulation of extracellular matrix (ECM), and carbohydrate metabolism were 
overrepresented among the study cohort. 
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 3 
Introduction 
 UTIs pose a significant burden on the health care system, with annual societal cost of $3.5 
billion in the United States.1 In select populations, UTIs can lead to pyelonephritis (kidney 
infections), causing renal scarring and long-term renal damage, the latter being exacerbated with 
repeated infections. Molecular mechanisms characterizing patients predisposed to recurrent UTIs 
have not been completely elucidated. Since the urinary proteome is a source of several host defense 
proteins, the analysis of the urinary proteome in these patients may provide insights into better 
understanding the etiology of recurrent UTI. 
The urinary tract has both mechanical and molecular host defense mechanisms.2-3 
Molecular host defense encompasses innate and adaptive immune responses involving immune 
cell activity and soluble factors secreted into urine such as uromodulin.  Mechanical defense 
include physical or anatomic barriers, such as the glycosaminoglycan layer lining the urothelium, 
complete voiding to eliminate residual urine with bacteria, and valvular mechanisms which isolate 
the bladder from the kidneys during micturition. Vesicoureteral reflux (VUR) is a congenital 
condition where failure of this lattermost anatomic mechanical host defense causes backwards 
flow of urine to the kidneys from the bladder and contributes to incomplete urinary clearance. It is 
a common condition that often resolves without symptoms or intervention.  However, during a 
UTI, VUR propagates the translocation of pathogenic bacteria from the bladder to the kidney, 
which can then lead to pyelonephritis and long-term sequalae such as renal scarring.4-5  Patients 
with VUR and a predisposition for recurrent UTIs are more likely to be at greater risk for long-
term kidney damage and may merit earlier medical or surgical intervention.4-6 While VUR itself 
is accurately diagnosed by current, albeit invasive, modalities, it is impossible to identify these 
patients who are at higher risk for UTI.  
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 4 
Due to the inability to determine the need for intervention, VUR patients are often 
overmanaged and overtreated both medically and surgically.6 Patients are placed on long-term 
daily antibiotic prophylaxis that can lead to antimicrobial resistance and associated side effects.6-
10  Serial assessment for continued presence of VUR exposes patients to invasive catheterization 
and ionizing radiation.  Surgical correction is undertaken for patients in whom the condition 
persists or for those who experience recurrent breakthrough UTIs despite antibiotic suppression.4-
6 The availability of minimally invasive endoscopic intervention has increased the number of 
patients who undergo surgery, suggesting a trend of overtreatment without clear indication or 
need.11 Beyond the economic impact, these potentially unnecessary interventions present risks of 
over exposure to antibiotics, surgery and anesthesia, all of which can impact pediatric growth and 
development.6-10, 12-13  
We hypothesized that there may be differences in host molecular mechanisms that 
distinguish VUR patients with recurrent UTIs and renal damage. If these differences become 
clinically relevant the management of this population would dramatically change.  To this aim, we 
performed a first-step pilot study comparing the urinary proteome of patients who underwent 
surgery for VUR with a history of recurrent UTI and renal scarring to that of healthy controls to 
determine if these cohorts can be distinguished by the urinary proteome. To categorize proteins 
that may be more characteristic of VUR and recurrent infection from those more likely indicative 
of renal damage, we compared proteomes to those from our previous study on patients with kidney 
damage resulting from ureteropelvic junction obstruction (UPJO). Furthermore, unlike prior 
studies, to reduce the potential bias of congenital kidney dysplasia often seen in higher grades of 
VUR, we focused only on children with lower grades of VUR.14-19  
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 5 
By concentrating on a well-defined urologic cohort, this pilot study sought to gain insight 
into recurrent UTI to serve as a foundation for future prospective, longitudinal studies that will 
involve children with VUR but no history of UTI. Differences identified in this population could 
ultimately provide guidance in improving the management of patients with VUR, particularly 
towards the development of better non-invasive diagnostic tools. Additionally, this work may 
contribute broader impact to elucidating mechanisms of recurrent UTI in other affected 
populations.  
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 6 
Experimental Methods 
Experimental Design and Statistical Rationale 
 All patients were identified from an Institutional Review Board (IRB)-approved protocol 
from the Boston Children’s Hospital Pediatric Urinary Proteome Program Initiative (PUPPI) 
repository.  VUR is graded from 1 to 5 (with 5 being the most severe), and we selected a cohort of 
22 patients who underwent open surgical correction for low grade of VUR (grades 1-3), history of 
recurrent febrile UTIs, and radiographic renal damage. Patients with more severe grades (grades 
4-5) were excluded due to the potential confounding factor of congenital renal dysplasia and 
kidney maldevelopment as the etiology of abnormal renal imaging.20  VUR grade was determined 
by voiding cystourethrogram (VCUG), and renal damage was defined as presence of renal cortical 
scarring on dimercaptosuccinic acid (DMSA) nuclear renal scan. Sample acquisition from VUR 
patients was by bladder catheterization via standard sterile technique on the day of surgery. None 
of the VUR patients had active infection as determined by urine culture.  
A control cohort of 22 patients was additionally selected from PUPPI. Individuals in this 
group had no history of urologic conditions (VUR, UTI, or renal damage), or other comorbid 
conditions. Patients identified as healthy controls were undergoing procedures such as 
circumcision, hypospadias repair, lysis of labial adhesions removal, or inguinal hernia/hydrocele 
repair. Urine samples were obtained by voiding or crede maneuver.  Due to the male predominance 
for these surgical procedures, there are a greater number of male samples available in the 
repository. Controls were selected to provide a similar age distribution to the VUR cohort, but 
gender and race distribution could not be achieved given limitations on available samples in the 
PUPPI repository. A pooled internal standard (PIS) was created from combining urine samples 
from 8 separate healthy controls. Aliquots of PIS were utilized as technical replicates for quality 
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 7 
control of signal normalization between different MS acquisitions and of bioinformatics 
processing. Demographic categorical and continuous variables were compared using Fisher’s 
exact test and Wilcoxon test, respectively, between the VUR and control groups for each cohort 
and between the VUR groups for the discovery versus validation cohorts (Table 1). 
 
Urinary Protein Extraction 
Samples were analyzed by urinalysis using a Siemens CLINITEK® status automated 
analyzer (Siemens, Tarrytown, NY) and confirmed there was no potential blood contamination or 
evidence of proteinuria. All samples were centrifuged at 4,500 ? g for 20 min to remove cellular 
debris, aliquoted, and frozen at -80°C prior to protein purification compliant with downstream MS 
analysis.21 Urine aliquots were subsequently thawed, desalted, and concentrated on 10 kDa MW 
cutoff filters. Samples were reduced in 10 mM dithiothreitol (DTT, Sigma Aldrich, St. Louis, MO) 
and alkylated in 25 mM iodoacetamide (IAA, Sigma Aldrich). Extracted urinary proteins were 
quantified by micro BCA assay following manufacturer’s instruction (Thermo Fisher Scientific, 
Waltham, MA).    
  
Peptide Isolation 
Extracted urinary proteins from each individual were processed separately via solid-phase 
reversible sample-preparation (SRS) beads, as previously described.22 Incubation was performed 
in a benchtop thermomixer (ThermoMixer C, Eppendorf, Germany) simultaneously shaking at 
1,400 rpm with collection of supernatants after centrifugation at 5,000 rpm for 30 seconds 
(Minispin, Eppendorf).  Briefly, 10 mg of dry SRS beads (~25 μL) was incubated with 0.01 M 
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 8 
NaOH (150 μL) for 3 min at room temperature (RT) and then rinsed twice with 150 μL phosphate-
buffered saline (PBS). Urinary proteins (80 μg) were dissolved in 100 μL of 0.5% SDS in PBS 
and incubated with the washed beads. Acetonitrile (100%, ACN, Thermo Fischer Scientific) was 
immediately added to reach a final concentration of 85% ACN to enable effective binding of 
proteins, as previously published.22 This mixture was incubated for 30 min at 1,400 rpm at RT. 
Samples were centrifuged to remove unbound proteins, and 8 M urea in PBS (150 μL) was added. 
Excess reagent was removed by 8 M urea in PBS (150 μL) and 80% ACN in PBS (150 μL) (3 
washes each). The beads were washed twice with 0.1 M ammonium bicarbonate (ABC, Sigma 
Aldrich) in heavy water (H218O) to label the glycosites for a separate prospective study and then 
placed in 150 μL of 0.1 M ABC in H218O for N-deglycosylation. 
N-deglycosylation was performed by adding 2 μL of peptide-N-glycosidase F (PNGase F, 
New England Biolabs, Ipswich, MA) to each sample in 2.5:100 enzyme-to-protein ratio and 
incubated overnight (20h) at 37°C. Released N-glycans were collected in supernatant after 
centrifugation and in two subsequent washes with 0.1% formic acid (150 μL, FA, Sigma-Aldrich) 
for additional analysis not assessed in this study. Proteins bound to the beads were resuspended in 
150 μL of 50 mM ABC in unlabeled H2O. Trypsin (2 μg, Promega, Madison, WI) was added to 
beads in 1:40 enzyme-to-protein ratio, with a second 2 μg added after 4h, and incubated at 37°C 
for 7h in total. Resulting peptides were collected in the supernatant after centrifugation. Samples 
were washed with 20% ACN (150 μL) and centrifuged, followed by wash and centrifugation with 
70% ACN (150 μL). All supernatants were pooled for each sample and stored at -20°C prior to 
MS analysis.   
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 9 
Mass Spectrometry Analysis and Database Search 
Dried peptides were reconstituted with 400 μL 5% FA/5% ACN. An aliquot of each sample 
was transferred into HPLC vial and placed in the autosampler at 4°C. Samples were individually 
analyzed on a Q-Exactive (ThermoFisher) coupled to a nanoflow UPLC system (Eksigent, Dublin, 
CA). The LC columns were packed in-house using Magic C18, 5 μm, 100 Å (Michrom 
BioResources/Bruker, Billrica, MA) into PicoTips (15 cm x 100 μm ID; New Objective, Woburn, 
MA). Peptides were separated utilizing a linear LC gradient from 95% solvent A (0.1% FA in 
water) and 5% solvent B (0.1% FA in ACN) to 70% solvent A and 30% solvent B over 120 min, 
followed by a steeper gradient to reach 5% solvent A and 95% solvent B over 7 min.  
Raw files were searched against Uniprot Homo sapiens and common contaminant 
databases (reviewed September 2015) using Proteome Discoverer 1.4 (ThermoFisher Scientific) 
and combination of Sequest and Mascot algorithms for database search (42,184 total entries 
searched). Tryptic peptides with a default charge states of 2+, 3+, and 4+ and up to one miscleaved 
site were considered. Mono-isotopic precursor mass tolerance was 10 ppm, and 0.02 Da search 
tolerance was permitted for fragment ion identification. Precursor and neutral loss peaks were 
removed in MS2 spectra. Carbamidomethylation of cysteine residues was set as fixed 
modification. Variable modifications were deamidation (N, N(18O), and Q) and oxidation (M). All 
data were searched against a combined target and decoy database. Confident peptide 
identifications were filtered at 1% false discovery rate (FDR) and identified proteins were matched 
by 2 or more spectra. Raw spectral data and Proteome Discoverer-generated MSF files have been 
deposited to the ProteomeXchange Consortium via the PRIDE partner repository with the dataset 
identifier PXD010469.23  
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 10 
Protein Quantification and Statistical Analysis 
The SpectR Spectral Analysis R Package was developed in-house to provide 
comprehensive quantitative analysis of data based on spectral counts (SC). The package in R is 
provided as supplemental file. MSF files were re-searched to assign a SC score to each peptide 
and only unique peptides were extracted for quantitation. The detection threshold was defined as 
raw SC ≥2, as non-zero values in this range were indistinguishable from zero. The latter values 
were assigned as missing and replaced with NA until after normalization. For non-missing raw SC 
data, normalization was performed using square root sum. In brief, the square root was normalized 
to the sum of all square root data and then squared, as shown below for n non-zero spectral count 
values among all samples analyzed. 
? ????
? ????????
?
?
 
Reproducibility of the processing was assessed using the 1,327 total proteins identified and 
quantified across the 5 technical replicates of PIS. Consistency of results was assessed based on 
pairwise comparisons of protein quantifications on peptides that were SC ≥2 (Supplemental Table 
1 and Supplemental Figure 1). Proteins that were identified with SC ≥2 in at least 7 patients in 
either VUR or control cohort were defined as reliably detected based on optimization of signal-to-
noise ratio.  This list of proteins was then subjected to permutation-based FDR to further filter the 
candidate protein lists for comparison. Non-parametric Wilcoxon testing was utilized to compare 
urinary protein abundances between VUR and control cohorts, and the resulting p-values for each 
protein ID were adjusted for multiple testing via Benjamini-Hochberg correction. Positive false 
discovery rate (q-value) was controlled at 7.5%. Hierarchical clustering was performed utilizing 
proteins meeting the above threshold. Fold change (FC) for each protein was determined using the 
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 11 
ratio of the mean value in the VUR cohort to that in the control cohort.  For ratios <1 where the 
mean value VUR was less than that of control, FC is expressed as -1/ratio to reflect downregulation 
in VUR. The relationship of FC and q-value for each protein was visualized by volcano plot 
(Figure 1). 
 
Functional Pathway Analysis 
In total, 80 proteins were differentially-regulated in the VUR patients compared to the 
control cohort (q-value <0.075; |FC| ≥1.2); 44 proteins showed increase in abundance while 36 
had decreased. These differentially-abundant urinary proteins were assessed via Functional 
Enrichment Analysis Tool (FunRich version 3.0).26  
 
Comparison of the Urinary Proteome of the VUR and UPJO Patients 
VUR data was compared to our previously published urinary proteome of pediatric 
ureteropelvic junction obstruction (UPJO) patients (750 proteins) and list of the candidate 
biomarkers for UPJO-associated renal damage (76 proteins) but unrelated to UTI.27 The 
comparison of VUR with UPJO data was performed to attempt segregating proteins that are more 
likely to be indicative of UTI from those that are associated with renal damage.  
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 12 
Validation of MS Results via Immunoaffinity-based Quantitation in Discovery and Independent 
Patient Cohorts 
Alpha-1-acid glycoprotein (orosomucoid, ORM1) was selected for validation by enzyme-
linked immunosorbent assay (ELISA R&D Systems, DAGP00, Minneapolis, MN). Initial 
verification was performed on remaining available urine from the original MS discovery cohort 
which included 19 VUR patients and 16 age-matched controls. A separate validation cohort of 20 
VUR patients with similar disease phenotype and 20 age-matched controls was then tested (Table 
1).  Urine aliquots (1 ml) were thawed and centrifuged at 4,000 ? g for 10 min to remove insoluble 
particles. Samples were diluted 1:10 in HPLC grade water (Thermo Fisher) and analyzed in 
replicates following manufacturer’s instructions. Optical density was measured at 450 nm with a 
correction at 540 nm using a FilterMax F3 Multi-Mode Microplate Reader (Molecular Devices, 
Sunnyvale, CA). Readouts were normalized to total urinary protein amount as determined by 
Bradford assay (Biorad, Hercules, CA) on a Beckman DU600 Spectrophotometer as previously 
described.28-31 Significant changes between ORM1 levels in VUR and control samples were 
assessed by Mann-Whitney-Wilcoxon test. 
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 13 
Results  
Altered Urinary Proteome in VUR Patients with UTI and Renal Scarring 
Demographics and clinical characteristics of the VUR and control groups in both the MS 
discovery and validation cohorts were not significantly different, as presented in Table 1. In total 
2,551 proteins were detected in the urine of our VUR patients and healthy individuals. To 
strengthen the comparative analysis, only proteins that were identified with SC ≥2 in more than 
30% of samples from disease and control cohort were considered, resulting in 964 proteins.  The 
threshold settings were determined based on analysis of the technical PIS replicates and 
optimization of signal-to-noise ratio, as mentioned above. Criteria of q-value <7.5% and |FC| ≥1.2 
were applied which resulted in 80 candidate protein biomarkers that may characterize the VUR 
patients with UTI and renal scarring based on urinary protein profiling (Figure 1 and Supplemental 
Table 2). Hierarchical clustering utilizing these 80 proteins indicated near complete segregation of 
the two cohorts supporting a different expression profile of the proteomes in the VUR and healthy 
urine (Figure 2).  
 
Functional Characterization of Differentially Expressed Proteins in VUR Patients  
Significantly-altered proteins between VUR patient and control cohort were functionally 
assessed via FunRich. The proteins eligible for FunRich’s functional enrichment are listed within 
Supplemental Tables 3-5. Regulation of complement cascade and hemostasis were the most 
significantly altered pathways in the VUR cohort compared to controls (Figure 3a, Supplemental 
Table 3). Over-representation of proteins involved in formation of the fibrin clot and activation of 
the platelet signaling was also observed. Extracellular matrix (ECM) proteins involved in integrin 
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 14 
family cell surface interaction and EphrinB-EPHB pathway were significantly affected in disease 
cohort (Figure 3a). Interestingly, many of acute phase response proteins that are known 
inflammatory plasma protein markers were significantly altered in the urine from the VUR patients 
compared to control. Proteins that were increased or decreased in abundance had distinctive 
molecular and biological functions (Figure 3b). In particular, we observed an increase in proteins 
involved in complement binding/activation (C3, C4A, C9, CFH and CFB) and in immune defense 
mechanism (ORM1 and ORM2) (Supplemental Table 4). On the contrary, proteins with hydrolase 
activity, cysteine-type peptidase (CP), and structural constituent of the ECM were downregulated 
(Supplemental Table 5). Additionally, certain protease inhibitors (PIs) were specifically down- or 
upregulated in the VUR patients. In particular, serine protease inhibitors (serpins) SERPINB3 and 
SERPINB4 were downregulated while SERPINA1, SERPINC1 and SERPIND1 were upregulated. 
Upregulation of two additional PIs, alpha-2-macroglobulin (A2M) and inter-? trypsin inhibitor 
heavy chain 2 (ITIH2) was also observed. Four glycoprotein-binding proteins were significantly 
regulated: complement factor H (CFH) and histidine-rich glycoprotein (HRG) were upregulated, 
while insulin-like growth factor 2 receptor (IGF2R) and SERPINA1 were downregulated.  
 
Comparison of VUR and UPJO Urinary Proteomes Demonstrates Limited Numbers of Shared 
Varying Proteins 
In a previous study, we focused on the discovery of putative urinary biomarkers of patients 
with renal damage caused by ureteropelvic junction obstruction (UPJO).27 We hypothesized that 
overlap of proteins related to both VUR and UPJO cohorts will reveal biomarkers indicative of 
renal damage commonly associated with injury. Proteins specifically regulated in one of the 
examined patient cohort may be considered indicative of disease-specific clinical traits.  
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 15 
In the case of the UPJO patients, 76 proteins were significantly altered compared to the 
control cohort. 27 This dataset was intersected with 80 proteins that were significantly changed in 
urine of the VUR patients. Eighteen overlapping biomarkers that were altered in both UPJO and 
VUR patients suggest there is a shared host response to inflammation and tissue repair resulting 
from either obstructive or UTI-related kidney damage. The remaining 62 proteins were distinct 
candidate biomarkers which may be characteristic of the VUR group and potentially of recurrent 
infection. Disease-specific alteration of the proteins that belong to the same protein class was 
observed. For example, inter-alpha-trypsin inhibitor heavy chain 1 (ITIH1) and 2 (ITIH2) were 
specifically altered in the urine of the UPJO and VUR patients, respectively. Altered expression 
of S100P was solely observed in UPJO, while changes in S100A7 was VUR specific. Upregulated 
serine protease inhibitors (SERPINA1, SERPINC1 and SERPIND1) in the VUR cohort were 
similarly regulated in UPJO patients.  However, downregulated SERPINs (SERPINB3 and 
SERPINB4) were VUR specific.  
 
ELISA Confirmation of ORM1 Levels in Discovery and Validation Cohorts 
Levels of ORM1 were initially cross-validated by ELISA in 19 VUR and 16 controls of 
the original MS cohort (p<0.01, Supplemental Figure 2). With this confirmation, an independent 
validation cohort of 20 VUR and 20 control patients were tested for ORM1. ELISA results 
confirmed significant upregulation of ORM1 in the independent cohort of VUR patients compared 
to controls (p<0.05, Figure 4). This independent immunoaffinity assays mirrored the quantification 
in the MS-based proteomic approach, supporting reliability of our spectral count-based protein 
quantitation. 
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Discussion 
We performed a comparative analysis of the urinary proteome in 22 healthy and 22 VUR 
patients with recurrent UTIs and renal scarring and identified 80 urinary proteins that were 
significantly altered in abundance. Unique to our study, we focused on a clinical cohort of children 
with low grade VUR (grade 1-3), history of recurrent UTIs, and radiographic confirmation of renal 
damage. Focusing on patients with low grade VUR favors discovery of proteins related to UTI and 
infection-induced renal damage as opposed to congenital renal dysplasia which is often observed 
in high grade VUR. This cohort enabled the identification of urinary proteins that may be related 
specifically to the VUR cohort (62 proteins) and a minor subpopulation of proteins that may be 
indicative of generalized renal damage (18 proteins). Functionally, these urinary proteins appeared 
to be involved in host defense mechanism and inflammation, including acute phase response and 
ECM remodeling, which are critical for clearing the pathogen and restoring homeostasis after 
resolving infection. With additional testing these candidate biomarkers may represent a pool of 
urinary proteins critical for distinguishing patients who are at higher risk for UTI and subsequent 
UTI-related renal scarring. Our discussion focuses on proteins that are known to directly or 
indirectly mediate inflammatory response and their putative role within the urine in the context of 
UTI. 
Immunomodulatory acute phase proteins (APP) are mainly secreted from the liver and their 
serum concentration increases (positive APPs) or decreases (negative APPs) by at least 25% in 
response to bacterial infection.32-33 Release of APPs is a host defense response that mediates 
pathogen clearance by recruitment of neutrophils and macrophages and sequestering serum iron 
critical for bacterial growth, while it also limits tissue injury during inflammation and mediates 
restoration of homeostasis post infection.33-34  Serum alteration of APPs, such as C-reactive protein 
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(CRP) or serum amyloid A (SAA) are rapid and large,32, 35-36 but the majority of APPs have a 
slower and moderate fluctuation occurring over days to weeks post infection. In our cohort 
numerous APPs that are altered in plasma during inflammation were also found altered in the urine 
of the VUR cohort. We investigated significantly-regulated urinary APPs, including those with 
moderate to low fold change. 
Upregulated urinary APPs are part of the complement system cascade (C3, C4-A, C4-B), 
involved in coagulation and fibrinolytic system (fibrinogen beta and gamma chains), protease 
inhibition (alpha-1-antitrypsin/SERPINA1)37 and protein transport (hemopexin), or have more 
complex systemic function (ORM1, ORM2 and alpha-2-macroglobulin/A2M).38 Notably, we did 
not detect significant alteration in urinary CRP and SAA, as their concentration peaks within the 
first couple of days of infection and normalizes after 1-2 weeks.36 The urine from our cohort was 
taken at a much later date when the children were not actively infected. A rapid increase in CRP 
levels activates the complement system34, 39 and thus increase of complement system proteins in 
the urine from the VUR cohort suggests that CRP was elevated during the initial phase of UTI. 
Surprisingly, several APPs that have been reported as downregulated in serum after infection (i.e., 
negative APPs) were significantly increased in our VUR cohort urine, such as transthyretin (i.e., 
prealbumin), antithrombin-III (SERPINC1) and coagulation factor XII. Future longitudinal studies 
will be needed to confirm how these negative APPs change in the urine along the course of 
infection and resolution phase. 
Using ELISA, we validated the quantitative MS upregulation of ORM1 in a separate cohort 
of patients. ORM1 is a 44 kDa glycoprotein synthetized in the liver and secreted in plasma during 
stress conditions. As an APP ORM1 has broad immunomodulatory and anti-inflammatory 
function, but its role in systemic inflammatory response during UTI is less defined.40-42  ORM1 
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inhibits macrophage and neutrophil infiltration into injured tissue which may be reason for 
increased survival rates observed during systemic inflammation and septic shock.43 The 
immunosuppression triggered by ORM1, however, leads to increased susceptibility for 
opportunistic infections.44-45  Although, ORM1 is limited as a standalone marker of susceptibility 
to UTI, it could serve as a marker for detection and progression of subclinical renal damage. 
Diagnostic potential of urinary ORM1 in the future may be extended for evaluating a risk from 
recurrent UTI in the VUR patients as a preceding, early-stage event that can eventually lead to 
UTI-associated renal damage.  
Secretion of APPs is often accompanied by changes in immunomodulatory peptides.46 
These peptides can be directly involved in inflammatory response, or their constitutive expression 
may be required for maintaining a homeostatic environment. In particular we closely investigated 
host-derived antimicrobial peptides (AMPs) and identified several AMPs in the urine. AMPs such 
as beta-defensin 1 (DEFB1), chathelicidin antimicrobial peptide (CAMP), and lysozyme (LYZ) 
were unaltered between cohorts, solely S100A7 (psoriasin) was found to be significantly 
downregulated in VUR patients compared to controls. S100A7 is the only member of S100 family 
that is regulated in our VUR cohort, and it has been identified as a major host-defense protein in 
vaginal fluid that protects from E. coli infection.47 This suggests that downregulation of S100A7 
in the urine of VUR patients may be indicative of less effective host innate immunity and higher 
risk for UTI. As both ORM1 and S100A7 have been involved in modulating immune response to 
infection and host-defense mechanism,44, 48-50 there may be a functional dependence between 
S100A7 down- and ORM1/2- upregulation that merits further investigation. 
Inflammation is a tightly regulated process which coincides with complex changes of the 
cell extracellular matrix (ECM).51-52 ECM composition and associated changes are critical for 
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pathogen attachment to the cell, as well as recruitment of immune cells to the infected site.51, 53-54 
Overrepresentation of regulated structural components of extracellular matrix (ECM), 
extracellular proteases (ECP) and inhibitors (ECPIs) was observed in VUR cohort (Figure 3). 
ECPs are promiscuous enzymes with complex substrate specificity and poorly defined sequence 
cleavage preference.55 Nevertheless, they are critical components of ECM that maintain a healthy 
tissue environment and modulate signaling events during disease such as inflammation.56-57 We 
found significant alteration of protein-based ECPIs in the urine of VUR patients (Figure 3b, 
Supplemental Table 4 and 5). The change in abundance of these inhibitory proteins was not 
uniform, but rather isoform specific. In particular, serpin peptidase inhibitors SERPINB3 and 
SERPINB4 were downregulated, while SERPINA1, SERPINC1 and SERPIND1 were upregulated 
in the urine of VUR patients. This pattern is intriguingly correlated with the tissue-specific 
expression of up- and downregulated SERPINs. According to the RNA expression database 
(www.proteinatlas.org), upregulated SERPINs are almost exclusively synthesized in the liver and 
gallbladder, whereas downregulated SERPINs originate from gastrointestinal tract, with a modest 
contribution from kidney and urinary bladder. At this stage, we are unable to distinguish the 
specific mechanism for the downregulation of SERPINB3 and SERPINB4, but many children with 
VUR and/or UTI have concomitant functional constipation and many are on antibiotic therapy and 
it is unclear if these interactions are responsible for the observed downregulation.   
SERPINC1 (Antithrombin III), a negative APP, and SERPIND1 (Heparin cofactor 2) are 
the two major heparin-dependent thrombin inhibitors in plasma that play a critical role in 
preventing coagulation and thrombosis.58 More recent reports also suggest their involvement in 
inflammation.59 Interestingly, binding of SERPINs to their targeted proteases increase up to 1000-
fold in a presence of glycosaminoglycan structures on the surface of host cells.60-61 This suggests 
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a critical interplay of cell-surface glycan structures and ECPIs in regulation and fine-tuning activity 
of ECPs. As protein glycosylation is an abundant PTM on the cell surface proteins and soluble 
proteins found in urine,62-63 alteration in a single protein that binds or modifies glycan structure 
can have a broader, systemic impact. In our study, we identified two glucosidases that were 
significantly downregulated in the urine of the VUR patients: ?-fucosidase 2 (FUCA2) and ?-N-
acetylgalactosaminidase (NAGA). FUCA2 is a plasma protein that cleaves ?-1,6-linked fucose 
that is attached to the N-acetylglucosamine of carbohydrate moieties of glycoproteins. 
Interestingly, deficiency in ?-fucosidase 1 (FUCA1) is a rare autosomal recessive disorder that 
along with other symptoms, is characterized by recurrent infections. 64 In contrast to FUCA2, 
FUCA1 is primarily expressed in tissues, and its abundance is unaltered between VUR patient and 
control urine samples. What remains unclear is whether the observed decrease in FUCA2 in the 
urine of VUR patients can predispose them to develop UTI, similar to autosomal recessive FUCA1 
deficiency disorder. The second glycosidase of interest, NAGA, is a lysosomal enzyme that 
hydrolyzes ?-N-acetylgalactosamine residues from glycolipids and glycopeptides. Similar to 
FUCA, NAGA deficiency results in impaired glycan degradation and accumulation of complex 
glycan structures in tissue as well as their excessive secretion in the urine.65 Changes in enzymes 
that regulate glycan metabolism can be correlated to observable changes in glycan structures 
identified in the urine of VUR patients. Reports on a competitive advantage of pathogenic bacteria 
that bind fucosylated glycan structures in the gastrointestinal tract urges exploration of this relation 
in the bladder epithelium.66-69 In future studies it will be critical to correlate the function of these 
carbohydrates in the bladder and in the urine to those observed in the gut. Such studies will 
determine whether these structures provide any advantage for bacterial growth or pathogen 
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adhesion to the surface of the host cells and may explain an increased susceptibility to infection 
observed in the VUR patients. 
While inflammatory response is beneficial for resolving infection, it damages surrounding 
tissues. Therefore, the inhibition of prolonged inflammatory response is critical for arresting 
further damage to the injured site. Proteins known to be involved in regulation of hemostasis and 
hemolysis were altered in the urine from the VUR patients compared to controls (Figure 3a). 
Hemostasis is reported to be  critical for the balance of host immune defense, being related to both 
innate and adaptive immune response.70 In contrast, hemolysis has been correlated with 
susceptibility to infection in various diseases and mouse models.71-73 It is well established that 
hemolysis-mediated release of iron can be beneficial for pathogen growth.74-75 A recent study 
additionally suggests that free heme decreases mobility of macrophages and prevents adequate 
pathogen clearance.76 To this end, disrupted hemostasis can have two detrimental outcomes which 
assist bacterial outgrowth: release of iron77-78 that benefits bacterial replication, along with release 
of heme that may impair macrophage-mediated phagocytosis of pathogenic bacteria.76 As urinary 
samples from VUR patients have been obtained at minimum one month after infection, 
longitudinal follow up over the longer course of time is needed to further understand if quantitative 
changes of these urinary proteins are short term or remains altered over prolonged period of time.   
We recognize that this study has limitations, including small sample size, the inherent 
clinical variability of patient selection and a single urinary proteome profiling after resolution of 
UTI. Controls were selected to provide a similar age distribution to the VUR cohort. Our VUR 
cohort was predominantly female, consistent with a known clinical preponderance of VUR, but 
the availability of female controls to allow for equal distribution was extremely limited. We have 
used our resources as the largest pediatric urologic department in the world to generate an 
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extremely well characterized clinical cohort that minimizes variability by controlling for grade of 
VUR, recurrent UTI and renal scarring. Although no clinical cohort is completely homogeneous, 
we identified significant changes in proteins that can contribute to susceptibility to UTI and UTI-
acquired renal damage in patients with low grade VUR. Whether these changes preceded or 
resulted from recurrent UTIs will be answered in follow-up longitudinal studies, using the 
information gained from this pilot study. These longitudinal studies will expand VUR patient 
cohorts to include asymptomatic VUR patients, and VUR patients with UTI but no renal scarring, 
as well as well-defined urine sampling over the longer course of recovery from a UTI. Together, 
this can not only aid in a finer separation of urinary biomarkers for susceptibility to infection from 
the ones that are indicative of renal damage as a consequence of recurrent UTIs, but also resolve 
temporal alteration of inflammatory markers after resolution of UTI. 
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Conclusions 
In order to better characterize VUR patients with a history of recurrent UTIs and renal 
scarring, we compared their urinary proteome profiles with that of healthy controls. Eighty proteins 
were differentially expressed in the patients’ urine. We identified 62 proteins that were solely 
altered in our chosen VUR cohort which may represent candidate biomarkers to characterize 
susceptibility of these patients to develop UTI, and 18 proteins that may more broadly represent 
renal injury. The former, for instance, include AMPs, protease inhibitors and proteins involved in 
glycoside catabolism. Further studies will be extended to distinct VUR cohorts in order to separate 
candidate biomarkers on the basis of susceptibility to UTIs and renal scarring. Ultimately, larger 
cohorts and longitudinal studies utilizing these findings will improve the diagnosis, delivery and 
cost-effectiveness of care for VUR patients. 
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MS Discovery Cohort Validation Cohort p value
VUR Control VUR Control
n 22 22 20 20
Age (years)
Median 5.3 5.7 6.2 5.4 0.44
Range 1.1-22.2 1.0-22.0 1.2-14.0 0.4-14.0
p=1.00 p=0.86
Gender
Male 13.6% (3) 59.1% (13) 20% (4) 50% (10) 0.40
Female 86.4% (19) 40.9% (9) 80% (16) 50% (10) 0.40
p<0.01 p=0.10
Reflux
1.00
Unilateral 40.9% (9) 45.0% (9)
Bilateral 59.1% (13) 55.0% (11)
Reflux Grade 
(Right)
0.25
None 18.2% (4) 25.0% (4)
Grade 1 18.2% (4) 0
Grade 2 36.4% (8) 40% (8)
Grade 3 27.3% (6) 35% (7)
Reflux Grade 0.57
(Left)
None 22.7% (5) 15.0% (3)
Grade 1 4.5% (1) 0
Grade 2 31.8% (7) 45.0% (9)
Grade 3 40.9% (9) 35.0% (7)
Grade 4 0 5.0% (1)
Antibiotic 
Prophylaxis 95.5% (21) 75% (15) <0.01
Renal Scarring 
(DMSA) 1.00
Unilateral 72.7% (16) 75.0% (15)
Bilateral 27.3% (6) 25.0% (5)
Table 1. Demographics of the VUR and Control Groups. Percentage values are listed with number
in parentheses for the VUR and matched control groups for both the MS discovery (left) and validation
(right) cohorts. The p value column reflects comparison between the VUR groups between the
discovery and validation cohorts. The p value for comparison between the VUR and control groups
within cohorts is listed below the comparison, where applicable. VUR, vesicoureteral reflux.
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Figure 1. Volcano Plot of VUR to Control Cohort Ratios for All Quantified Proteins. Of the 964
robustly identified and quantified proteins in the VUR and control cohorts, 80 proteins were deemed
differentially regulated candidate markers by meeting criteria of q-value <7.5% and FC ≥+1.2 (up-
regulated in VUR; green) or ≤-1.2 (down-regulated in VUR; red). Specific candidate proteins of interest
as determined by biological network analysis are indicated. FC, fold change.
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Figure 2. Hierarchical Clustering of Differentially Regulated Proteins Demonstrates
Segregation of the VUR and Control Cohorts. Eighty proteins met criteria of corrected q-value FDR
<7.5% and |FC| ≥1.2. Hierarchical clustering utilized the normalized SC for these proteins in each
sample, with color intensity based on SC value. The resulting dendrograms demonstrated
segregation and clustering for the majority of the VUR and control samples (horizontal axis). The
candidate markers also clustered and segregated based on whether they were up- or down-
regulated in the VUR cohort (vertical axis).
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Figure 3. Functional Characterization of VUR-regulated Proteins. (A) Overrepresented biological
pathways from all regulated proteins in the urine of the VUR patients. Percentage of proteins indicates the
VUR-altered proteins over the entire proteins in the pathway (bars), while significance of the enrichment is
represented by the p-value (enrichment and reference 0.05 p-value). (B) Representative molecular function
was separately assigned to the urinary proteins that were up- (green) or downregulated (red). Asterix
represents p-value <0.05. Functional enrichment was performed via FunRich version 3.0. ECM, extracellular
matrix; n.s., not significant; VUR, vesicoureteral reflux.
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Figure 4. ELISA Quantification of ORM1 in ValidationCohort.
A validation cohort consisting of VUR (n=20) and control (n=20) samples separate from the
discovery cohort were tested. Mean levels with standard error are shown, demonstrating a
statistically significant elevation of ORM1 levels in the VUR cohort by Mann-Whitney-Wilcoxon test.
ORM, orosomucoid; VUR, vesicoureteral reflux.
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